FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2

Fei Xu(Beijing Chao-Yang Hospital, Capital Medical University), Xiaohua Wu(Fudan University Shanghai Cancer Center)

Molecular Cancer

March 3, 2021

10.1186/s12943-021-01340-8

Cited by 139

Related Papers

Preventing <scp>BRCA</scp>1/<scp>ZBRK</scp>1 repressor complex binding to the <i>GOT2</i> promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation

|Molecular Oncology|2019|47

m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways

|Oncogene|2025|13

Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer

|Unknown|2023|0

Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

|Unknown|2023|0

Supplementary Data from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

|Unknown|2023|0